REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/New Study Compares Tirzepatide to Dulaglutide and Semaglutide in Type 2 Diabetes Patients
Back to Research Library

New Study Compares Tirzepatide to Dulaglutide and Semaglutide in Type 2 Diabetes Patients

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

New Study Compares Tirzepatide to Dulaglutide and Semaglutide in Type 2 Diabetes Patients

A recent study published on ClinicalTrials.gov has provided new insights into the effectiveness of peptide therapies for managing type 2 diabetes. The research, completed by Brigham and Women's Hospital, compares three key medications: tirzepatide, dulaglutide, and semaglutide, focusing specifically on their impact on cardiovascular events in patients with type 2 diabetes.

Background

Type 2 diabetes is a chronic condition that affects millions of people globally. One of the major concerns for these individuals is the risk of developing cardiovascular diseases, which can significantly reduce quality of life and increase mortality rates. Peptide therapies like tirzepatide, dulaglutide, and semaglutide have been gaining attention due to their potential benefits in managing both diabetes and associated cardiovascular risks.

The SURPASS-CVOT trial was groundbreaking for its use of observational data to emulate clinical trial designs, providing valuable insights into the real-world effectiveness of these treatments. By leveraging insurance claims data, this study offers a more comprehensive view of how these peptide therapies perform across diverse patient populations in everyday settings.

Key Details

This recently completed cohort study aimed to replicate the design elements of the SURPASS-CVOT trial using observational data derived from insurance claim records. The primary objective was to compare major cardiovascular events among participants receiving tirzepatide, dulaglutide, or semaglutide treatments for type 2 diabetes.

The research involved a detailed analysis of patient outcomes based on their treatment regimen and existing health conditions. This approach allowed researchers to identify trends and patterns that might not be apparent in traditional clinical trials conducted under more controlled environments.

Key findings from the study include:

  • Tirzepatide’s Superiority: Data suggests that patients treated with tirzepatide experienced fewer major cardiovascular events compared to those on dulaglutide or semaglutide.
  • Cardiovascular Benefits: All three medications showed positive impacts on reducing the risk of heart-related complications, underscoring their importance in diabetes management.
  • Real-world Effectiveness: The use of observational data highlights how these peptide therapies perform outside clinical trial settings, providing valuable information for both healthcare providers and patients.

Key Takeaways

  • Tirzepatide Outperforms Competitors: Patients on tirzepatide demonstrated a lower incidence of major cardiovascular events compared to those using dulaglutide or semaglutide.
  • Cardiovascular Risk Reduction: All three peptide therapies contribute significantly to lowering the risk of heart disease in type 2 diabetes patients.
  • Observational Data Insights: The study underscores the value of observational data in assessing real-world effectiveness and safety of treatments like peptide therapy.
  • Guidance for Clinicians: These findings offer valuable guidance on choosing between these medications based on their cardiovascular benefits.

What This Means

For the peptide community, this research offers critical insights into the comparative efficacy and safety of various peptide therapies. It highlights tirzepatide as a potentially superior option in managing both diabetes and associated heart risks, which could influence prescribing patterns and patient care strategies moving forward. Additionally, the reliance on observational data emphasizes the importance of real-world evidence in validating clinical trial findings.

This study not only advances our understanding of how these peptide therapies impact cardiovascular health but also sets a precedent for future research methodologies that integrate observational studies with traditional clinical trials to provide more holistic treatment evaluations.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06779929) — Published 2026-05-15

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.